Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
VO
Vogenx, Inc. VOGX
$18.12
▼ -1.20%
($-0.22)
⚡ High Volume
🎈 Low Float
Open
$18.34
Prev Close
$18.34
Day Range
$17.44 – $19.09
52W Range
$12.95 – $38.41
Market Cap
$300.82M
Beta
-14.29
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Shares Out. | 14,860,000 |
| Website | vogenx.com ↗ |
| Phone | 18009817183 |
| Employees | 5 |
| Listed | 2026-08-12 |
About Vogenx, Inc.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
Vogenx, Inc. is a publicly traded company under the ticker symbol VOGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-11-01)